Top Page
Charmacy Pharmaceutical Co., Ltd. Class H
(2289)
Charmacy Pharmaceutical Co., Ltd. Class H (2289) vs. iShares MSCI Hong Kong ETF (EWH)
Charmacy Pharmaceutical Co., Ltd. Class H Business Overview & Revenue Model
Charmacy Pharmaceutical Co., Ltd. Class H Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.24B | 4.44B | 4.40B | 4.18B | 3.79B | 3.99B |
| Gross Profit | 320.54M | 324.76M | 292.74M | 268.61M | 234.12M | 237.40M |
| EBITDA | 153.32M | 155.71M | 136.92M | 121.03M | 107.55M | 111.03M |
| Net Income | 48.28M | 53.28M | 51.34M | 90.47M | 23.15M | 40.56M |
Balance Sheet | ||||||
| Total Assets | 3.49B | 3.46B | 3.25B | 2.87B | 2.76B | 2.80B |
| Cash, Cash Equivalents and Short-Term Investments | 509.97M | 563.15M | 644.76M | 503.81M | 641.76M | 602.02M |
| Total Debt | 1.05B | 1.70B | 1.37B | 1.19B | 1.33B | 1.25B |
| Total Liabilities | 2.90B | 2.84B | 2.65B | 2.27B | 2.26B | 2.30B |
| Stockholders Equity | 591.83M | 618.69M | 597.81M | 594.48M | 504.10M | 502.55M |
Cash Flow | ||||||
| Free Cash Flow | 274.87M | 90.31M | -137.39M | 35.46M | -44.58M | 79.10M |
| Operating Cash Flow | 280.72M | 106.04M | -96.54M | 44.05M | -19.54M | 131.08M |
| Investing Cash Flow | -5.82M | -15.64M | 39.34M | 71.76M | -24.40M | -54.78M |
| Financing Cash Flow | 0.00 | ― | 101.26M | -191.21M | 74.40M | -2.68M |
Charmacy Pharmaceutical Co., Ltd. Class H Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$8.75B | 24.83 | 6.77% | 2.72% | 29.81% | 10.40% | |
62 Neutral | HK$3.78B | 20.09 | 5.07% | 3.81% | 0.33% | -44.28% | |
60 Neutral | HK$786.24M | 15.08 | 8.12% | 8.03% | ― | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
40 Underperform | HK$643.44M | -0.58 | -69.05% | ― | -43.86% | -217.25% |
Charmacy Pharmaceutical Co., Ltd. Class H Corporate Events
Charmacy Pharmaceutical Co., Ltd. held an Extraordinary General Meeting on December 12, 2025, where all proposed resolutions were approved by shareholders. Key decisions included the approval of a new framework loan agreement with Jiangyao Group Co., Ltd., the appointment of Pan-China Certified Public Accountants LLP as the company’s auditors, and the abolishment of the Board of Supervisors. These changes are expected to streamline the company’s governance structure and potentially enhance its financial operations.
Charmacy Pharmaceutical Co., Ltd. has announced an extraordinary general meeting (EGM) scheduled for December 12, 2025, to discuss several key resolutions. These include a new framework loan agreement with Jiangyao Group Co., Ltd., the appointment of Pan-China Certified Public Accountants LLP as auditors, and proposed amendments to the company’s articles of association. These resolutions, if approved, could impact the company’s financial arrangements and governance structure, potentially influencing its market positioning and operational efficiency.
Charmacy Pharmaceutical Co., Ltd. announced a proposed change of auditors due to the approaching end of ShineWing’s service term, in compliance with the Administrative Measures for Selection and Appointment of Accounting Firms. ShineWing, the current auditor since 2017, will resign following the upcoming extraordinary general meeting. The company has proposed appointing Pan-China Certified Public Accountants LLP as the new auditor, subject to shareholder approval. The Board and Audit Committee believe Pan-China’s industry experience and technical competence align with the company’s audit requirements, ensuring no compromise in audit standards or effectiveness.
Charmacy Pharmaceutical Co., Ltd. has announced the renewal of its continuing connected transactions through a new framework loan agreement with Jiangyao, a controlling shareholder of the company. This agreement, effective from January 1, 2026, for a term of three years, allows Jiangyao to provide a loan facility to Charmacy, subject to statutory approval. The new agreement is considered a continuing connected transaction under the listing rules, requiring shareholder approval and annual review. An independent board committee and financial adviser have been appointed to assess the fairness and reasonableness of the agreement.
Charmacy Pharmaceutical Co., Ltd. has announced a proposal to abolish its Board of Supervisors, subject to shareholder approval at an extraordinary general meeting. The functions of the Board of Supervisors will be assumed by the Audit Committee of the Board of Directors, aiming to improve corporate governance and operational standards. Additionally, the company plans to amend its Articles of Association to align with these changes, which are expected to enhance compliance with legal and regulatory requirements.